While Johnson & Johnson has been cleared to acquire Synthes, it must sell its wrist fractures unit, known as DVR, to Biomet. The FTC concluded, without this stipulation, Johnson & Johnson and Synthes would control 70 percent of the market for the wrist fracture treatment systems and harm competition.
Related Articles on Orthopedic Devices:
Mazor Launches C-Onsite Spinal Implant Verification Software on Global Scale
Premier Healthcare Alliance Announces New Agreements for Spinal Implants
